Biotech · Private company
Fore Biotherapeutics
Track this companyFree. Adds Fore Biotherapeutics to your Dealase workspace and tells you when its record changes.
Clinical trials52 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline5
- FORE8394Phase 2 · Advanced Unresectable Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- PlixorafenibPhase 2 · Cancer Harboring BRAF AlterationsClinicalTrials.gov · fetched Nov 12, 2026
- CobicistatPhase 1 · Healthy ParticipantsClinicalTrials.gov · fetched Nov 12, 2026
- PlixorafenibPhase 1 · Healthy ParticipantsClinicalTrials.gov · fetched Nov 12, 2026
- PLX8394Phase 1 · MelanomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered GliomaEARLY_PHASE1 · RECRUITING · started Apr 7, 2025ClinicalTrials.gov NCT06610682 · fetched Nov 12, 2026
- A Study of the Effects of Food and Cobicistat on Plixorafenib Pharmacokinetics in Healthy Participants.PHASE1 · COMPLETED · started Apr 24, 2024ClinicalTrials.gov NCT06385119 · fetched Nov 12, 2026
- A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF AlterationsPHASE2 · RECRUITING · started Feb 21, 2023ClinicalTrials.gov NCT05503797 · fetched Nov 12, 2026
- A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid TumorsPHASE1_PHASE2 · COMPLETED · started Apr 1, 2015ClinicalTrials.gov NCT02428712 · fetched Nov 12, 2026
- Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.PHASE1 · TERMINATED · started Feb 1, 2014ClinicalTrials.gov NCT02012231 · fetched Nov 12, 2026